AstraZeneca Diprivan Pediatric ICU Sedation Safety Study Requested By FDA
Executive Summary
AstraZeneca is planning an additional study of Diprivan for pediatric ICU sedation after finding an increased rate of mortality with the injectable anesthetic in a trial seeking the indication.